Clareo Health | A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Trimeris
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV-1 infected adults or adolescents \>=16 years of age;
HIV-1 RNA \>=5000 copies/mL;
prior experience or documented resistance to each of the 3 currently available classes of ARV drugs (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors).
You may not be if
history of prior use of Fuzeon or T-1249;
female patients who are pregnant or breastfeeding, or who plan to become pregnant during the study;
current severe illness;
currently taking drugs affecting the immune system, HIV vaccine, or investigational agents for any conditions other than HIV/AIDS.
